ArticleClinical sarcoma research2013
Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis.
Article in Clinical sarcoma research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- UK guidelines for the management of soft tissue sarcomas.British journal of cancer · 2025Guideline
- Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.British journal of cancer · 2021Review
- Desmoid Fibromatosis: Management in an Era of Increasing Options.Current oncology reports · 2021Review
- Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma.Cancer management and research · 2021Article
- The value of the black fiber sign on T1-weighted images for predicting stability of desmoid fibromatosis managed conservatively.European radiology · 2020Observational
- Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects.Frontiers of medicine · 2019Review
- Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2017Article
- Desmoid-Type Fibromatosis: Who, When, and How to Treat.Current treatment options in oncology · 2017Review
- Pazopanib, a promising option for the treatment of aggressive fibromatosis.Anti-cancer drugs · 2017Article
- Advances in sarcoma diagnostics and treatment.Oncotarget · 2017Review
- AKT1 and BRAF mutations in pediatric aggressive fibromatosis.Cancer medicine · 2016Article
- Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.Current treatment options in oncology · 2016Article
- UK guidelines for the management of soft tissue sarcomas.Clinical sarcoma research · 2016Review
- Pazopanib: a novel treatment option for aggressive fibromatosis.Clinical sarcoma research · 2016Article
- Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis.Oncology and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDesmoid tumours/aggressive fibromatosis (DT/AF) are infrequent soft-tissue neoplasms. They usually behave as indolent diseases. However, they may grow locally infiltrating or compressing adjacent structures. The role of local treatment is limited and only a few drugs have shown activity. CASES PRESENTATION: We report the outcome of two patients affected by progressive DT/AF treated with the angiogenesis inhibitor pazopanib in two different institutions. Both patients achieved dramatic improvement in their symptoms and radiological signs of response. The clinical benefit lasted for more than 1 year and it is still ongoing.
conclusionsPazopanib is an active treatment in DT/AF. It is the first time this has been reported.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.